**
As the Democratic Republic of the Congo (DRC) grapples with a severe Ebola outbreak, healthcare experts have initiated a pioneering treatment trial in the Ituri region, marking a significant milestone in global health response efforts. Just six weeks following the World Health Organization’s (WHO) declaration of the outbreak as a public health emergency on 17 May, the first patients have begun participating in a clinical trial aimed at reducing the mortality rates associated with the Bundibugyo strain of the virus.
Swift Action in the Face of Crisis
The urgency surrounding the outbreak is palpable in Bunia, the capital of Ituri province, where local residents express growing frustration over the unfolding crisis. Neema Haba, a banana seller and mother of three, shared her concerns: “I hope these drug trials proceed quickly. Financially, we are being driven to the brink by this outbreak, and nothing is going right. We are struggling to provide for our children.”
As of 9 July, the outbreak has resulted in 1,792 confirmed cases and 625 fatalities, with the WHO indicating that the situation remains in an “expansion phase.” Without a vaccine or approved treatments available, the response has relied heavily on traditional methods such as case identification, isolation, and contact tracing. However, challenges abound, including a lack of community trust in health authorities and disruptions to frontline services due to financial disputes.
Challenges for Frontline Workers
The work of healthcare professionals and support teams is fraught with danger. Ovide Maliabo, a driver for a burial team in Rwampara, highlighted the community’s mistrust, stating, “At one point, we narrowly escaped being lynched. It’s a shame that we aren’t being financially supported.” His colleague, Bahati John, reported that they had endured physical assaults, underscoring the perilous conditions under which they operate. “We haven’t seen a single penny,” he lamented, pointing to the financial strain on workers who are vital to the outbreak response.
These challenges are compounded by logistical issues, including a local airport closure that has hindered efforts to secure essential supplies and resources. Although government officials assert that financial support has been allocated, many frontline workers remain sceptical, raising concerns about their safety and well-being.
Innovative Treatment Approaches
Amidst these trials, the Partners treatment trial has commenced, testing two potential therapies: remdesivir, an antiviral developed by Gilead Sciences, and MBP134, a monoclonal antibody created by Mapp Biopharmaceutical. Patients will be randomly assigned to receive one of these treatments, a combination of both, or only standard supportive care.
Professor Laurens Liesenborghs from the Institute of Tropical Medicine in Antwerp, who is involved in the trial, explained that both drugs have shown promise in animal studies against the Bundibugyo strain. “We need to determine if they can indeed lower mortality in humans,” he stated, emphasising the critical nature of this research. While Bundibugyo typically has a lower fatality rate than the notorious Zaire strain, it still claims around one in three lives.
The trial aims to recruit between 700 and 1,000 participants, with sufficient supplies for 1,200 patients already secured from Gilead and the US government. This study is particularly noteworthy as it includes participants of all ages, including pregnant and breastfeeding women, who are often excluded from clinical research. The potential for life-saving treatment in such vulnerable populations underscores the trial’s significance.
Global Collaboration and Future Prospects
Professor Amanda Rojek from the University of Oxford praised the rapid initiation of the trial, highlighting the critical role of robust scientific leadership in the DRC, which has a history of conducting significant research during previous outbreaks. “We’re very proud of the team led by INRB [the DRC’s National Biomedical Research Institute] that we’ve managed to achieve this in just six weeks since the outbreak was first announced,” she noted.
As the trials progress, WHO officials remain cautious but optimistic, stating that the outcome could reshape treatment approaches for Ebola. Furthermore, another trial is set to launch, investigating whether administering a drug called obeldesivir to individuals in contact with confirmed cases can prevent the onset of the disease.
Why it Matters
The launch of these treatment trials represents a vital step in addressing the Ebola crisis in the DRC, showcasing the importance of swift and coordinated global health responses. The outcome of this research may not only provide effective therapies for the current outbreak but could also inform future responses to similar infectious disease threats. As communities rally for support, the implications of these trials extend beyond the immediate crisis, potentially reshaping the landscape of Ebola treatment and prevention globally.
